Atara Biotherapeutics (ATRA) Liabilities and Shareholders Equity (2013 - 2026)

Atara Biotherapeutics' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 67.77% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.3 million (down 75.11% YoY) and the FY2025 annual result came in at $20.2 million, down 81.45% from the prior year.
• Liabilities and Shareholders Equity was $20.0 million for Q1 2026 at Atara Biotherapeutics, down from $20.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $436.1 million in Q2 2022 and bottomed at $20.0 million in Q1 2026.
• A 5-year average of $187.3 million and a median of $165.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 4.53% — and 2025, when it plunged 81.45%.
• Atara Biotherapeutics' Liabilities and Shareholders Equity stood at $376.4 million in 2022, then plunged by 56.03% to $165.5 million in 2023, then plunged by 34.08% to $109.1 million in 2024, then plunged by 81.45% to $20.2 million in 2025, then fell by 1.18% to $20.0 million in 2026.
• Business Quant data shows ATRA's Liabilities and Shareholders Equity at $20.0 million in Q1 2026, $20.2 million in Q4 2025, and $30.2 million in Q3 2025.